 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
4 News |  |
- ||| pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX
Trial completion, Combination therapy, Monotherapy, Metastases: CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov) - Jan 23, 2024
P2, N=125, Completed, Sponsor: CytomX Therapeutics
Active, not recruiting --> Completed
- || pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov) - Feb 23, 2023
P2, N=125, Active, not recruiting, Sponsor: CytomX Therapeutics
Active, not recruiting --> Completed Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Apr 2023
- ||||| praluzatamab ravtansine (CX-2009) / CytomX
Clinical, P2 data: #SABCS22 | Poster | P4-01-15 Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced #breastcancer (ABC). Dr. Kathy Miller @stolaney1 @ErikaHamilton9 @FilipaLynce @CejalvoM #bcsm (Twitter) - Dec 8, 2022
- praluzatamab ravtansine (CX-2009) / CytomX
Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC) (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_967;
P2
Time to event analyses, such as PFS, were confounded by higher-than-expected toxicity at a starting dose of 7 mg/kg. The toxicity profile was generally consistent with a DM4 payload.
- ||| pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX
Enrollment closed, Enrollment change, Combination therapy, Monotherapy, Metastases: CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov) - Aug 9, 2022
P2, N=125, Active, not recruiting, Sponsor: CytomX Therapeutics
The toxicity profile was generally consistent with a DM4 payload. Recruiting --> Active, not recruiting | N=200 --> 125
- || praluzatamab ravtansine (CX-2009) / CytomX
P1/2 data, Journal: Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial. (Pubmed Central) - May 19, 2022
CD166 is a novel, ubiquitously expressed target. CX-2009 is the first conditionally activated antibody-drug conjugate to CD166 to demonstrate both translational and clinical activity in a variety of tumor types.
- ||| pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov) - Mar 29, 2022
P2, N=200, Recruiting, Sponsor: CytomX Therapeutics
CX-2009 is the first conditionally activated antibody-drug conjugate to CD166 to demonstrate both translational and clinical activity in a variety of tumor types. N=150 --> 200 | Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
- pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX, ImmunoGen
Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_320;
P2
This study will also evaluate safety and tolerability, pharmacokinetics, and antidrug antibodies with praluzatamab ravtansine as monotherapy and in combination with pacmilimab. This trial is enrolling (NCT04596150).
- | praluzatamab ravtansine (CX-2009) / CytomX, ImmunoGen
Preclinical, Journal: The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by Zr-immuno-PET in xenograft bearing mice. (Pubmed Central) - Aug 4, 2021
CX-2009 is optimally capable of targeting CD166-expressing tumors when compared with its derivatives, implying that enzymatic activation inside the tumor, required to allow CD166 binding, does not limit tumor targeting. Because CX-2009 does not bind to mouse CD166, however, reduced targeting of healthy organs should be confirmed in ongoing clinical Zr-immuno-PET studies.
- pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX, ImmunoGen
[VIRTUAL] Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) () - Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_282;
P2
This study will also evaluate safety and tolerability, pharmacokinetics, and antidrug antibodies with CX-2009 as monotherapy and in combination with pacmilimab. This trial is enrolling (NCT04596150).
- ||| praluzatamab ravtansine (CX-2009) / CytomX
Trial completion, Metastases: PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (clinicaltrials.gov) - Jan 11, 2021
P1/2, N=99, Completed, Sponsor: CytomX Therapeutics
This trial is enrolling (NCT04596150). Active, not recruiting --> Completed
- ||| pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX
Enrollment open, Combination therapy, Monotherapy, Metastases: CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov) - Jan 6, 2021
P2, N=150, Recruiting, Sponsor: CytomX Therapeutics
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX
New P2 trial, Combination therapy, Monotherapy, Metastases: CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov) - Oct 22, 2020
P2, N=150, Not yet recruiting, Sponsor: CytomX Therapeutics
- pacmilimab (CX-072) / CytomX, praluzatamab ravtansine (CX-2009) / CytomX, ImmunoGen
[VIRTUAL] A Phase 2, open-label study to evaluate the safety and efficacy of the probody therapeutic (Pb-Tx) CX‑2009 in metastatic HR-Positive/HER2-negative breast cancer (mHR+/HER2− BC) and of CX-2009 as monotherapy and in combination therapy with CX-072 in metastatic triple-negative breast cancer (TNBC) () - Oct 2, 2020 - Abstract #SABCS2020SABCS_1085;
This trial is actively enrolling. Email address for questions or comments: gpaton@cytomx.com
- praluzatamab ravtansine (CX-2009) / CytomX, ImmunoGen
[VIRTUAL] Intratumoral activation and phase 1/2 clinical activity of CX-2009, a probody drug conjugate (PDC) targeting CD166 (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_747;
P1/2
The relationship between normalized intratumoral DM4 and tumor volume changes support the premise that accumulation of payload toxin is related to anti-tumor activity. The correlation between activated CX-2009 and target expression suggests a role for CD166 in intratumoral accumulation of activated CX-2009.
- ||| praluzatamab ravtansine (CX-2009) / CytomX
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (clinicaltrials.gov) - Jul 21, 2020
P1/2, N=99, Active, not recruiting, Sponsor: CytomX Therapeutics
The correlation between activated CX-2009 and target expression suggests a role for CD166 in intratumoral accumulation of activated CX-2009. Recruiting --> Active, not recruiting | N=150 --> 99 | Trial completion date: Dec 2021 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Oct 2020
- CX-072 / CytomX, CX-2009 / CytomX, Immunogen
[VIRTUAL] CX-2009, a CD166-directed Probody drug conjugate, alone and combined with CX-072, anti–PD-L1 Probody therapeutic, in patients (Pts) with advanced cancer including HER2- negative breast cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2909;
- CX-2009 / CytomX, Immunogen
[VIRTUAL] CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). (Poster Board 18) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1648;
P1/2
Phase II expansion has begun in pts with HR+/HER2- BC. The Q2W schedule will continue to enroll pts to define the RP2D.
- CX-2009 / CytomX, Immunogen
[VIRTUAL] Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009: A masked probody drug conjugate to CD166. (Poster Board 329) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1549;
P1/2
Preliminary DR and POPPK simulations support further evaluation of 7 mpk CX-2009 Q3W in selected cohort expansions. Research Funding: CytomX Therapeutics, Inc.
- |||| praluzatamab ravtansine (CX-2009) / CytomX
Enrollment open, Metastases: PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (clinicaltrials.gov) - Jun 5, 2017
P1/2, N=150, Recruiting, Sponsor: CytomX Therapeutics
Research Funding: CytomX Therapeutics, Inc. Not yet recruiting --> Recruiting
- ||||| praluzatamab ravtansine (CX-2009) / CytomX
New P1/2 trial, Metastases: PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (clinicaltrials.gov) - May 10, 2017
P1/2, N=150, Not yet recruiting, Sponsor: CytomX Therapeutics